DLBCL
Haematology · 2019–2026
7decisions
5medicines
5carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| loncastuximab tesirine Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received two or more prior lines of systemic therapy. | Mar 2026 | Not recommended | no section in document |
| glofitamab Treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after one or more lines of systemic therapy in patients ineligible for autologous… | Jul 2025 | Recommended with restriction | unclear |
| polatuzumab vedotin Treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) in patients with an International Prognostic Index (IPI) score of 3–5, administered in… | Mar 2025 | Recommended with restriction | input received Lymphoma Group · Rare Cancers Australia · Leukaemia Foundation · Lymphoma Australia |
| epcoritamab Treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, who have previously… | Nov 2024 | Recommended | input received Rare Cancers Australia · Leukaemia Foundation |
| polatuzumab vedotin Treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) in patients with an international prognostic index (IPI) score of 3-5, in combination… | Nov 2022 | Not recommended | input received Lymphoma Australia · Leukaemia Foundation · Rare Cancers Australia |
| selinexor Treatment of adult patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) after at least two lines of systemic therapy. | Jul 2021 | Not recommended | input received Rare Cancers Australia · Lymphoma Australia · Leukaemia Foundation · Eastern Cooperative Oncology Group |
| polatuzumab vedotin Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in patients ineligible for stem cell transplantation, in combination with bendamustine and… | Nov 2019 | Not recommended | 2 individuals |
Who spoke
Rare Cancers Australia · Leukaemia Foundation · Lymphoma Australia · Lymphoma Group · Eastern Cooperative Oncology Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.